Once completed in 2029, our new 35,000-square-foot radioligand therapy (RLT) site in Winter Park, Florida will expand our manufacturing footprint and optimize the delivery of RLT medicines to patients in the southeast US.
RLT is a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue.
Key Facts About the Site
2029
35K
1 of 5
Featured Stories
Designing for the Future: The Next Era of Biomedical Research in San Diego
Thierry Diagana, California Sites Head at Novartis, shares the vision for a new research hub that will power future drug discovery.
Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future
As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.
How This Former Army Officer Helps Deliver Cancer Treatments to Patients
Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.
